

Special Issue

Molecular and Genetic Diagnosis and Targeted Therapy of Myeloproliferative Neoplasms

Message from the Guest Editors

Myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPN NOS, are among the most common myeloid neoplasms. Their treatments and their prognosis are different. However, they can show overlapping clinical presentations and are sometimes difficult to distinguish from each other. Therefore, it is critical to perform correct diagnosis and stratification on patients with MPNs. With the advancement of new technologies such as NextGen sequencing, there has been rapid progress in the understanding about the pathogenesis, the diagnosis, the prognosis, and the targeted therapy of MPNs. The purpose of this Special Issue is to present the current advancements in the diagnosis and the prognosis prediction of MPNs. This Special Issue welcomes reviews as well as original research articles. The submission deadline will be extended to May 2024.

Guest Editors

Dr. Jinming Song

Dr. Ling Zhang

Dr. Andrew Kuykendall

Deadline for manuscript submissions

closed (31 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164025

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)